These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Effect of insulin-induced hypoglycaemia on absorption of unmodified insulin after subcutaneous or intramuscular injection. Grønlund B; Frandsen H; Lauritzen M; Nielsen SL; Madsbad S Diabet Med; 1991 Jan; 8(1):13-7. PubMed ID: 1826237 [TBL] [Abstract][Full Text] [Related]
13. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme. Prakash J; van Loenen-Weemaes AM; Haas M; Proost JH; Meijer DK; Moolenaar F; Poelstra K; Kok RJ Drug Metab Dispos; 2005 May; 33(5):683-8. PubMed ID: 15673598 [TBL] [Abstract][Full Text] [Related]
14. [Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case]. Elorriaga-Sánchez F; Corrales-Bobadilla H; Sosa-Trinidad E; Domínguez-Quezada B Gac Med Mex; 2001; 137(3):249-52. PubMed ID: 11432094 [TBL] [Abstract][Full Text] [Related]
15. [ACE inhibitors may cause hypoglycemia in patients with diabetes]. Lakartidningen; 1995 Oct; 92(42):3923. PubMed ID: 7564661 [No Abstract] [Full Text] [Related]
16. Beta-blockers, diabetes, and hypoglycemia: risky business? Levinson PD Med Health R I; 2001 Mar; 84(3):81-2. PubMed ID: 11280134 [No Abstract] [Full Text] [Related]
17. The physiological rationale for oral insulin administration. Arbit E Diabetes Technol Ther; 2004 Aug; 6(4):510-7. PubMed ID: 15321008 [TBL] [Abstract][Full Text] [Related]
18. The responses of adrenocorticotrophic hormone and cortisol to insulin-induced hypoglycaemic stress in man are unimpaired during chronic converting enzyme inhibition. Morganti A; Ambrosi B; Sala C; Bochicchio D; Turolo L; Cianci L; Checchini M; Zanchetti A J Hypertens Suppl; 1985 Nov; 3(2):S121-4. PubMed ID: 3003299 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]